Scarica l'app Stockscreener
43.58
7.26%
-3.41
Dopo l'orario di chiusura:
43.40
-0.18
-0.41%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Nektar Therapeutics Borsa (NKTR) Ultime notizie
NKTR Stock Eyes Worst Day In Over 3 Years On Rezpeg Data: William Blair Still Sees A Durability Edge - Yahoo Finance
Jefferies Analyst Defends Nektar Therapeutics (NKTR) Amid 21% St - GuruFocus
Why This Biotech Took A 21% Hit On Promising Alopecia Results - Investor's Business Daily
Nektar Therapeutics (NKTR) Shares Drop After Rezpegaldesleukin T - GuruFocus
William Blair Reaffirms Outperform on Nektar Therapeutics (NKTR) Amid Rezpeg Data Advances - GuruFocus
Nektar Therapeutics (NKTR) Stock Forecasts - Yahoo! Finance Canada
This Biotech Had Good News for Hair Loss Sufferers. So Why Is the Stock Sinking? - Barron's
Nektar REZPEG Data Show Durable Hair Regrowth, Set Up Phase III Alopecia Trial - Yahoo Finance
/UPDATE — Nektar Therapeutics/ - Morningstar
Nektar Therapeutics stock faces a trial data checkpoint - AD HOC NEWS
Nektar Therapeutics (NKTR) Climbs 2.20% to $60.55, Pressing Toward Upper RangeChaikin Flow - siam.in
Nektar presents early biomarker data for eczema drug at EADV 2026 - StreetInsider
Nektar Therapeutics (NKTR) Unveils Promising Rezpegaldesleukin B - GuruFocus
New Biomarker Data Presented in a Late Breaking Oral Presentation at EADV Congress 2026 Showing Early Molecular Responses to Rezpegaldesleukin Across Multiple Immune Pathways Dysregulated in Patients with Atopic Dermatitis - PR Newswire
Asset turnover of Nektar Therapeutics – HAN:ITH0 - TradingView
How New Rezpegaldesleukin Durability and Mechanistic Data Could Impact Nektar Therapeutics (NKTR) Investors - Yahoo Finance
What Could Nektar Therapeutics (NKTR) New Rezpegaldesleukin Data Mean For Its Case? - Yahoo Finance
How Investors May Respond To Nektar Therapeutics (NKTR) New Phase 2b Data Presentations - Simply Wall Street
Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Shareholders to Connect - ACCESS Newswire
Nektar awarded $90 million in Lilly rezpeg dispute - The Pharma Letter
Nektar to present alopecia areata drug data at EADV congress - Investing.com
Nektar to present alopecia areata drug data at EADV congress By Investing.com - Investing.com Nigeria
After treatment stops, Nektar will present six-month data on severe hair loss - Stock Titan
Two funds hold 9.8% of Nektar Therapeutics (NKTR), with three parties reporting the same stake. - Stock Titan
Nektar Therapeutics (NKTR) Stock Dropped, So What Is Driving Attention Now? - Simply Wall Street
Nektar Therapeutics (NKTR) Dropped, So What Is Driving Attention Now? - Yahoo Finance
BTIG reiterates Buy rating on Nektar Therapeutics, $178 price target - TradingView
StockWatch: Nektar Shares Flat as $90M Jury Verdict Less than Sought in Lilly Suit - Genetic Engineering and Biotechnology News
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Nektar Therapeutics (NKTR) And Encourages Stockholders to Reach Out - ACCESS Newswire
A Jury Awarded Nektar $90 Million From Eli Lilly. Here’s Why the Stock Barely Moved - Yahoo Finance
Nektar Therapeutics Director Roy Whitfield Reports Acquisition of RSUs and Stock Options - Kalkine Media
Form 4 Nektar Therapeutics For: 25 September By Investing.com - Investing.com Nigeria
Nektar Therapeutics (NKTR) grants a director 2,000 shares upon vesting and options to buy 4,000 more. - Stock Titan
A director receives 2,000 stock units alongside 4,000 options at Nektar Therapeutics (NKTR). - Stock Titan
Director Robert Chess also received 2,000 stock units from Nektar Therapeutics (NKTR), vesting in one year. - Stock Titan
A director receives an option to buy 4,000 Nektar Therapeutics (NKTR) shares at $57.66 each. - Stock Titan
Nektar Therapeutics awarded $90 million in jury verdict against Eli Lilly By Investing.com - Investing.com South Africa
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
Eli Lilly owes Nektar $90 mln in drug collaboration dispute, US jury says - reuters.com
Microsoft, Nike, Nektar Therapeutics - TradingView
Nektar Therapeutics Wins $90M Lilly Verdict - grafa.com
Nektar Therapeutics stock rises on $90M jury verdict vs Lilly - Investing.com
Lilly ordered to pay Nektar $90M in damages over rezpeg dispute - FirstWord
Jury awards Nektar Therapeutics $90M in rezpeg dispute with Eli Lilly - app.dealroom.co
Nektar prevails in legal battle with Lilly over broken rezpeg partnership - biospace.com
Update: Nektar Wins $90 Million Jury Verdict Against Eli Lilly Over Rezpegaldesleukin Deal - Yahoo Finance
Eli Lilly Did Breach Implied Covenant of Good Faith With Nektar Therapeutics, Jury Funds - TradingView
Why is Nektar Therapeutics stock climbing today? By Investing.com - Investing.com Australia
Nektar Gets $90 Million Jury Award in Breach Suit Against Eli Lilly — Update - Morningstar
Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data - Yahoo Finance
Why is Nektar Therapeutics stock climbing today? - Investing.com
Nektar Wins $90 Million Jury Verdict Against Eli Lilly Over Rezpegaldesleukin Deal - Yahoo Finance
Form 8K Nektar Therapeutics For: 25 September By Investing.com - Investing.com India
Nektar Therapeutics awarded $90 million in jury verdict against Eli Lilly - Investing.com Canada
Nektar gains 5% as jury awards $90M plus interest in Lilly trial - TradingView
Nektar Therapeutics awarded $90M jury verdict against Eli Lilly over rezpegaldesleukin dispute - TradingView
Nektar TherapeuticsJury Finds Lilly Breached Implied Covenant Of Good Faith In License Agreement - TradingView
[8-K] NEKTAR THERAPEUTICS Reports Material Event - Stock Titan
Alopecia Areata Market Analysis 2036: Industry Trends, Market Size, and Emerging Therapeutic Developments – DelveInsight | Sun Pharma, Pfizer, Soterios, Abbvie, Legacy Healthcare, Nektar Therapeutics - Barchart.com
Eli Lilly Hit With $90M Verdict In Nektar's Rezpeg Breach Suit - Law360
Nektar Therapeutics (NKTR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Nektar Therapeutics stock gains 2.98 percent on trial watch - AD HOC NEWS
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Nektar Therapeutics (NKTR) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Nektar Therapeutics wins US$90M jury award in Lilly licence case - Mugglehead Investment Magazine
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):